Trial Profile
A Prospective, Multicenter, Randomized, Open-label, Active-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Imatinib at 400 or 600 mg in Treatment of Patients With Gastro-intestinal Stromal Tumor in First Line Medical Treatment
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Masitinib (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 15 Jun 2019 Trial has been completed in France, according to European Clinical Trials Database record.
- 12 Dec 2018 Status changed from recruiting to discontinued.
- 28 Jul 2018 The study has been discontinued in Spain.